NEWS & EVENTS

Events

I4ID 2022, 23-24 November, 2022, Lyon (France)

Inotrem will attend Immunotherapies & Innovations For Infectious Diseases 6th Congress. It is looking forward to meeting you at its lecture presenting the results of its last two clinical trials, ASTONISH and ESSENTIAL, targeting TREM-1 for the treatment of Septic Shock and Critically-Ill COVID-19 patients.

Read More »
Press releases

Inotrem announces that its ESSENTIAL Phase II study for the treatment of critically ill COVID-19 patients meets its primary and key secondary endpoints

Paris (France), October 25. 2022. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, announced today at the European Society of Intensive Care Medicine’s Annual Congress, held in Paris, positive results for ESSENTIAL, its Phase II clinical trial in COVID-19 patients hospitalized in

Read More »
Press releases

Inotrem and the Crohn’s & Colitis Foundation sign a R&D collaboration agreement to support the development of a new therapeutic approach in Inflammatory Bowel Disease (IBD)

Paris (France), April 14th 2022. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the development of a new therapeutic approach in IBD.

Read More »
Events

Sachs European Life-Science CEO Forum

March 1-2. 2022, Sachs European Life-Science CEO Forum (on line). Inotrem will participate to the 15th Annual European Life Sciences CEO Forum (ELSF) that will take place on the 1st-2nd of March 2022 and is part of the Sachs Spring Life Sciences Week. Inotrem is pleased to participate to this global bio-pharma industry event and, through

Read More »
Press releases

Inotrem appoints Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program Targeting Chronic Inflammatory Diseases

Paris, France. November 9, 2021. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies targeting the TREM-1 pathway, announced today the appointment of Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program. The creation of this position comes at a time of significant growth for Inotrem as

Read More »
Events

Immunotherapies & Innovations for Infectious Diseases Congress

November 15-16. 2021. Lyon, France. Inotrem is pleased to participate to the fifth edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2021). Fostering quality interactions between hundreds of pharmaceutical companies, research labs, service providers, technology developers, and clinicians, I4ID has become a central event contributing to the development of

Read More »
Press releases

Inotrem receives approval to expand nangibotide clinical trial in critically ill COVID-19 patients and receive additional public funding of €45 million

Paris, July 12th. 2021. Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in COVID-19 patients from both the French and Belgian competent authorities.

Read More »
Press releases

Inotrem announces positive outcome of interim futility analysis for its Phase IIB ASTONISH trial in septic shock patients to demonstrate nangibotide efficacy

Paris. June 10th, 2021. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today that the ASTONISH Independent Data Monitoring Committee (IDMC) completed the planned safety and efficacy assessment for futility of the company’s ongoing Phase IIB ASTONISH trial in septic shock

Read More »
Events

Health Bioscience Research Industry Days

March 16-17. 2021 (fully digital format). Inotrem is thrilled to participate to HYBRID 2021, the first Health Bioscience Research Industry Days that represents the complete ecosystem in life science in France, organized by ARIIS, AVIESAN, Leem, BPI France and France Biotech. During two days, researchers, biotech companies and representatives of

Read More »
Press releases

CoviTREM-1 consortium, composed of Inotrem, Nancy and Limoges teaching hospitals, announces it has completed patients’ inclusion for its COVID-19 Phase IIa clinical study

Paris, Limoges, Nancy (France). February 3rd, 2021 – Today, the CoviTREM-1 consortium, regrouping Nancy and Limoges teaching hospitals with Inotrem, a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, announces that it has completed the patients’ inclusion of its Phase IIa clinical study with a total of 60 patients

Read More »